Evogene Statistics
Total Valuation
Evogene has a market cap or net worth of $7.99 million. The enterprise value is $9.80 million.
| Market Cap | 7.99M |
| Enterprise Value | 9.80M |
Important Dates
The last earnings date was Tuesday, August 18, 2026, before market open.
| Earnings Date | Aug 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evogene has 13.54 million shares outstanding. The number of shares has increased by 51.18% in one year.
| Current Share Class | 15.80M |
| Shares Outstanding | 13.54M |
| Shares Change (YoY) | +51.18% |
| Shares Change (QoQ) | +25.28% |
| Owned by Insiders (%) | 8.51% |
| Owned by Institutions (%) | 5.63% |
| Float | 14.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.82 |
| Forward PS | 9.69 |
| PB Ratio | 1.39 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.57, with a Debt / Equity ratio of 0.36.
| Current Ratio | 3.57 |
| Quick Ratio | 3.52 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -182.75% and return on invested capital (ROIC) is -78.17%.
| Return on Equity (ROE) | -182.75% |
| Return on Assets (ROA) | -37.80% |
| Return on Invested Capital (ROIC) | -78.17% |
| Return on Capital Employed (ROCE) | -137.76% |
| Weighted Average Cost of Capital (WACC) | 6.40% |
| Revenue Per Employee | $43,605 |
| Profits Per Employee | -$238,763 |
| Employee Count | 38 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 2.71 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.06% in the last 52 weeks. The beta is 0.70, so Evogene's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -58.06% |
| 50-Day Moving Average | 0.55 |
| 200-Day Moving Average | 0.77 |
| Relative Strength Index (RSI) | 44.72 |
| Average Volume (20 Days) | 253,833 |
Short Selling Information
The latest short interest is 53,001, so 0.34% of the outstanding shares have been sold short.
| Short Interest | 53,001 |
| Short Previous Month | 232,078 |
| Short % of Shares Out | 0.34% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.09 |
Income Statement
In the last 12 months, Evogene had revenue of $1.66 million and -$9.07 million in losses. Loss per share was -$0.90.
| Revenue | 1.66M |
| Gross Profit | -1.12M |
| Operating Income | -14.32M |
| Pretax Income | -16.58M |
| Net Income | -9.07M |
| EBITDA | -13.97M |
| EBIT | -14.32M |
| Loss Per Share | -$0.90 |
Balance Sheet
The company has $9.32 million in cash and $2.10 million in debt, with a net cash position of $7.22 million or $0.53 per share.
| Cash & Cash Equivalents | 9.32M |
| Total Debt | 2.10M |
| Net Cash | 7.22M |
| Net Cash Per Share | $0.53 |
| Equity (Book Value) | 5.77M |
| Book Value Per Share | -0.24 |
| Working Capital | 7.81M |
Cash Flow
In the last 12 months, operating cash flow was -$10.95 million and capital expenditures -$24,000, giving a free cash flow of -$10.97 million.
| Operating Cash Flow | -10.95M |
| Capital Expenditures | -24,000 |
| Depreciation & Amortization | 351,000 |
| Net Borrowing | -511,000 |
| Free Cash Flow | -10.97M |
| FCF Per Share | -$0.81 |
Margins
| Gross Margin | -67.59% |
| Operating Margin | -864.33% |
| Pretax Margin | -1,000.48% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Evogene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -51.18% |
| Shareholder Yield | -51.18% |
| Earnings Yield | -113.55% |
| FCF Yield | -137.31% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 8.71% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 25, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jul 25, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Evogene has an Altman Z-Score of -32.2 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -32.2 |
| Piotroski F-Score | 1 |